## **ACO Name and Location**

Healthy Communities ACO, LLC 255 Lafayette Ave. Suffern, New York 10901

# **ACO Primary Contact**

Primary Contact Name	Michele Muldoon
Primary Contact Phone Number	(845) 368-5083
Primary Contact Email Address	Michele_Muldoon@bshsi.org

# **Organizational Information**

## ACO participants:

ACO Participants	ACO Participant in Joint Venture (Enter Y or N)
Bon Secours Charity Health System Medical Group, P.C.	No

## ACO governing body:

	Member		Member's	Membership	ACO Participant TIN	
Last Name	First Name	Title/Position	Voting Power	Туре	Legal Business Name/DBA, if Applicable	
Leahy	Mary	MD, Chair	yes	ACO participant	223636986  Bon Secours Charity Health System Medical Group, P.C.	
Devir	John		yes	Medicare Beneficiary Representative		
Wollenhorst	John		yes	ACO representative, Parent Organization		
Kenniff	Peter	CFO	yes	ACO participant	223636986  Bon Secours Charity Health System Medical Group, P.C.	
Muldoon	Michele	VP, Population	Yes	ACO participant	223636986	

		Health			Bon Secours Charity Health System Medical Group, P.C.
Etienne	Mill	MD, Medical	Yes	ACO	223636986
		Director		participant	Bon Secours Charity Health System Medical Group, P.C.
Beenstock	Steven	MD	Yes	ACO	223636986
				participant	Bon Secours Charity Health System Medical Group, P.C.
Evers	Martin	MD	Yes	ACO	223636986
				participant	Bon Secours Charity Health System Medical Group, P.C.
Shapiro	Deborah	MD	Yes	ACOparticipant	223636986
					Bon Secours Charity Health System Medical Group, P.C.
Bernstein	Scott	MD	Yes	ACO	223636986
				participant	Bon Secours Charity Health System Medical Group, P.C.
Miller	Dean	MD	Yes	ACO	223636986
				participant	Bon Secours Charity Health System Medical Group, P.C.
Ferrara	Lisa	MD	Yes	ACO	223636986
				participant	Bon Secours Charity Health System Medical Group, P.C.
Keenan	June	SVP,CRHI	yes	ACO representative, parent organization	

#### **Key ACO clinical and administrative leadership:**

Corey Deixler	ACO Executive
Mill Etienne	Medical Director
Patty Ariel	Compliance Officer
Michele Muldoon	Quality Assurance/Improvement Officer

#### Associated committees and committee leadership:

Committee Name	Committee Leader Name and Position
Quality Improvement Committee	Mary Leahy, MD, CEO

### Types of ACO participants, or combinations of participants, that formed the ACO:

• ACO professionals in a group practice arrangement

### **Shared Savings and Losses**

### **Amount of Shared Savings/Losses**

N/A

#### **Shared Savings Distribution**

N/A

# **Quality Performance Results**

### 2016 Quality Performance Results:

ACO#	Measure Name	Rate	ACO Mean
ACO-1	CAHPS: Getting Timely Care, Appointments, and Information	N/A	79.9
ACO-2	CAHPS: How Well Your Providers Communicate	N/A	92.63
ACO-3	CAHPS: Patients' Rating of Provider	N/A	91.93
ACO-4	CAHPS: Access to Specialists	N/A	83.52
ACO-5	CAHPS: Health Promotion and Education	N/A	60
ACO-6	CAHPS: Shared Decision Making	N/A	75.28
ACO-7	CAHPS: Health Status/Functional Status	N/A	71.82

			1
ACO- 34	CAHPS: Stewardship of Patient Resources	N/A	27.52
ACO-8	Risk-Standardized, All Condition Readmission	N/A	14.7
ACO- 35	Skilled Nursing Facility 30-Day All-Cause Readmission Measure (SNFRM)	N/A	18.17
ACO- 36	All-Cause Unplanned Admissions for Patients with Diabetes	N/A	53.2
ACO- 37	All-Cause Unplanned Admissions for Patients with Heart Failure	N/A	75.23
ACO- 38	All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions	N/A	59.81
ACO-9	Ambulatory Sensitive Conditions Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)	N/A	9.27
ACO- 10	Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8)	N/A	14.53
ACO- 11	Percent of PCPs who Successfully Meet Meaningful Use Requirements	N/A	82.72
ACO- 39	Documentation of Current Medications in the Medical Record	N/A	87.54
ACO- 13	Falls: Screening for Future Fall Risk	N/A	64.04
ACO- 14	Preventive Care and Screening: Influenza Immunization	N/A	68.32
ACO- 15	Pneumonia Vaccination Status for Older Adults	N/A	69.21
ACO- 16	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow Up	N/A	74.45
ACO- 17	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	90.98
ACO- 18	Preventive Care and Screening: Screening for Clinical Depression and Follow- up Plan	N/A	53.63
ACO- 19	Colorectal Cancer Screening	N/A	61.52
ACO- 20	Breast Cancer Screening	N/A	67.61
ACO- 21	Preventive Care and Screening: Screening for High Blood Pressure and Follow- up Documented	N/A	76.84
ACO- 42	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	N/A	77.72
ACO-	Diabetes Mellitus: Hemoglobin A1c Poor Control	N/A	18.24

27			
ACO- 41	Diabetes: Eye Exam	N/A	44.94
ACO- 28	Hypertension (HTN): Controlling High Blood Pressure	N/A	70.52
ACO- 30	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	85.05
ACO- 31	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	N/A	88.67
ACO- 33	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)	N/A	79.67

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples.

# **Payment Rule Waivers**

No, our ACO does not use the SNF 3-Day Rule Waiver.